Resources Repository
-
ReviewPublication 2017Model-Based Economic Evaluation of Treatments for Depression: A Systematic Review
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies …
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies evaluating the cost-effectiveness of treatments for depression and examine the appropriateness of different modelling technique for simulating the natural course of depression. The review yielded 41 model-based studies, of which 21 used decision trees (DTs), 15 used cohort-based state-transition Markov models (CMMs), two used individual-based state-transition models (ISMs), and three used discrete-event simulation (DES) models. Just over half of the…
State-Transition | Mental Health | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Health/Medicine -
ReviewPublication 2017Quality of Life as an Outcome of Opioid Use Disorder Treatment
The recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there …
The recent opioid epidemic has prompted renewed interest in opioid use disorder treatment, but there is little evidence regarding health-related quality-of-life (HRQoL) outcomes in treatment programs. Measuring HRQoL represents an opportunity to consider outcomes of opioid use disorder treatment that are more patient-centered and more relevant to overall health than abstinence alone. This systematic literature review explores the extent to which the collection of HRQoL by opioid treatment programs is documented in the treatment program literature.…
Preferences/Values | Mental Health | Health Outcomes | Evidence Synthesis | Chronic Disease/Risk | Social Determinants | Health Systems | Economics/Finance | Health/Medicine -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Preferences/Values | Mental Health | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Health Systems | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America | Europe -
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
State-Transition | Mental Health | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | Europe -
ArticlePublication 2016Estimating Benefits of Regulations Affecting Addictive Goods
The question of how to evaluate lost consumer surplus in benefit−cost analyses is controversial. There …
The question of how to evaluate lost consumer surplus in benefit−cost analyses is controversial. There are clear health benefits of regulations that curb consumption of goods with health risks, such as tobacco products and foods high in fats, calories, sugar, and sodium. Yet, if regulations cause consumers to give up goods they like, the health benefits they experience may be offset by some utility loss, which benefit−cost analyses of regulations need to take into account.…
Preferences/Values | Mental Health | Decision Theory | Benefit-Cost Analysis | Health/Medicine -
ArticlePublication 2016Measuring Benefits of Opioid Misuse Treatment: HRQOL of Opioid-Dependent Individuals and Spouses
This study sought to understand how the general public views the quality of life effects …
This study sought to understand how the general public views the quality of life effects of opioid misuse and opioid use disorder on an individual and his/her spouse, measured in terms used in economic evaluations. The study design was a cross-sectional internet survey of a US population-representative respondent panel conducted December 2013-January 2014, with a total of 2054 randomly selected adults, of whom 51.1% were male. The mean individual utility ranged from 0.574 for active injection…
Preferences/Values | Mental Health | Health Outcomes | Chronic Disease/Risk | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
State-Transition | Mental Health | Cost-Effectiveness Analysis | Health/Medicine | North America -
ArticlePublication 2011Cost-Effectiveness of Psychotherapy for Cluster C Personality Disorders
This article, published in the Journal of Clinical Psychiatry, describes a probabilistic Markov cohort model …
This article, published in the Journal of Clinical Psychiatry, describes a probabilistic Markov cohort model that compares the cost-effectiveness of five treatment modalities (long-term outpatient psychotherapy, short-term and long-term day hospital psychotherapy, and short-term and long-term inpatient psychotherapy) for patients with cluster C personality disorders. The analyses are conducted from the societal and payer perspectives. Patient-level data comes from 466 patients with cluster C personality disorders who were admitted to 6 specialist centers of psychotherapy…
State-Transition | Mental Health | Cost-Effectiveness Analysis | Health/Medicine | Europe -
ArticlePublication 2010Cost-Effectiveness of Psychotherapy for Cluster B Personality Disorders
This article, published in the British Journal of Psychiatry, presents a probabilistic Markov cohort model …
This article, published in the British Journal of Psychiatry, presents a probabilistic Markov cohort model that compares the cost-effectiveness of three treatment strategies (outpatient, day-hospital and inpatient psychotherapy) for patients with cluster B personality disorders. Patient-level data is used to populate the model and the analyses are conducted from the societal and payer perspectives. From the societal perspective, the findings show that the incremental cost-effectiveness ratio (ICER) of day hospital psychotherapy compared to outpatient psychotherapy…
State-Transition | Mental Health | Cost-Effectiveness Analysis | Health/Medicine | Europe